<<<LifePoint Logo>>>						CORPORATE HEADQUARTERS
									1205 South Dupont Street
									Ontario, CA 91761
									Tel: 909-418-3000
									Fax: 909-418-3003



November 20, 2003

Dear Stockholders and Friends of LifePoint:

   It gives me great pleasure to report that LifePoint has made good progress
on the re-start plans we outlined in our last letter in August 2003. Our major
focus has been first, to hire the experienced personnel to help LifePoint
achieve it goals; next, to successfully re-launch the IMPACT Test System with
an enhanced, updated product, and then to implement a definitive, focused plan
to facilitate rapid market acceptance of the product. Since our last letter,
the Company has accomplished the following:

* Obtained stockholder approval for and completed the second close of a $13
million financing, consisting of two parts: $8.8 million in new cash and
conversion of $4.2 million in secured debt to equity.

* Successfully renegotiated over $3 million in unsecured debt to pay out less
than $1.5 million during the first 12 months of renewed operations.

* Hired proven professionals for: Vice President of Operations, Director of
QSR and Regulatory and Instrument Production Manger/ Manufacturing Engineer.

* Appointed Stan Yakatan as Chairman of the Board and added Nuno Brandolini
as an independent director.

* Received a patent for enhancing THC (marijuana) immunochemical assays.

Financing

  Achieving the two objectives needed for LifePoint to meet the criteria for
the second close of our recent financing was the critical starting point for
our revised efforts to help us to continue the introduction, manufacturing and
marketing of the LifePoint(r) IMPACT(r) Test System.  As soon as LifePoint
completed the consent statement review process with the SEC, we quickly
finalized and mailed the consent to our shareholders.  Additionally, during
this time, we also continued to negotiate with our unsecured vendors to meet
the goal to pay less than $1.5 million on over $3 million of outstanding
payables during the 12 months following restart of operations. We accomplished
both of those tasks in mid September, and were able to complete our $13 million
financing on September 24, 2003.  This financing consisted of two parts, new
cash into LifePoint of over $8.8 million, and conversion of all secured debt of
a little more than $4.2 million into equity.  This financing significantly
improved our balance sheet over our status in January 2003. At this time, not
only do we have more cash, but also we will have substantially reduced our
unsecured payables for the next 9 months by over $750K through the unsecured
creditor settlement program, in addition to eliminating our secured debt of
over $4.2 million.  This financing allowed LifePoint to begin implementation of
our re-start plan.

Human Resources

   Our first objective was to hire the experienced personnel with the
prerequisite skills to move LifePoint to the next stage of its life. Although
all of the senior and key employees remained with LifePoint through the
difficult period until financing was obtained, we still needed to hire some key
employees.

   Mr. Kevin McNerney was hired as VP of Operations and he will oversee product
manufacturing, manufacturing engineering, materials planning, purchasing,
distribution and warehousing. Mr. McNerney has over 20 years experience in both
the medical device and pharmaceutical industries, with hands-on experience in
start-up organizations and fortune 100 companies. Since November 2000, Mr.
McNerney held several key positions, including Vice President of Operations, at
Power Medical Intervention. Prior to that, Mr. McNerney was Vice President of
Operations at Premier Laser Systems, and Director of Corporate Engineering at
Leiner Health Products. From 1994 until 1999, Mr. McNerney held various
manufacturing positions at B.Braun / McGaw, Mentor Corporation, Pharmaseal
Division of Baxter HealthCare, Surgikos Division of Johnson & Johnson and
Kendall Company. His successes include product automation and process scale-up,
MRP implementation, and ISO 9001 certification, all critical skills that will be
needed at LifePoint over the next 18 months. We are excited about the depth and
breadth of experience that Kevin adds to our senior management team.

   In addition to Kevin, we have also added David B. Goldberg, Ph.D. as
Director of Regulatory and Quality Systems.  David has over 16 years of
experience in the pharmaceutical, biologic and clinical care industry.
Dr. Goldberg was recently the Director of Validation and Toxicology for Alpha
Therapeutic Corporation, where he managed corporate quality validation for all
facility, new manufacturing processes, computer, quality control and equipment
validations required for all FDA submissions and license approvals. David
concurrently held the position of Director of Toxicology and was responsible
for all Research and Development Quality Assurance activities.

   We appointed a new director, Nuno Brandolini, to represent the largest
investor in LifePoint, and have appointed Stan Yakatan as our Chairman. Stan
Yakatan has extensive experience in sales, marketing and business development
and as a Chairman and CEO in a variety of diagnostic, biotechnology and
pharmaceutical companies. Stan is Chairman, President and Chief Executive
Officer of Katan Associates, and he is also Chairman of BioComm, an Australian-
based venture capital group.  From 1969 to 1994, Mr. Yakatan advanced to
executive officer positions with Sandoz, New England Nuclear, Dupont, ICN
Pharmaceuticals, and New Brunswick Scientific. Stan has proven expertise in
building successful businesses and his extensive global contacts should be
beneficial in helping to quickly transition the significant international
interest in the IMPACT Test System into a profitable business. More
importantly, I will now be able to relinquish the demands of the Chairman
position, and have more time to focus on the execution of our business plan.
Lastly, the addition of a non-executive Chairman is consistent with the current
trend of companies to improve corporate governance.

   We have also successfully hired experienced middle management including
instrument production manager / manufacturing engineer and QA/QC manager.

   With these additions, the senior and key management team is in place,
although we are still looking for a few additional middle management positions
in operations. Until some of these hires are completed, LifePoint may find it
difficult to quickly ramp up our product production.  We continue to fill all
immediate needs with either consultants or other employees on an interim basis.
However, we are confident that we will be able to continue to hire the skilled
personnel needed to assure that LifePoint continues to be able to scale up the
manufacturing and to quickly implement our sales efforts in the field.

Manufacturing & Product Support

   Our second objective is to successfully re-launch the IMPACT Test System.
As we outlined in our last letter, during our cash constrained period, we
completed testing the product enhancements made in January and finished our
first round of design and process improvement to improve product performance,
improve product reliability and manufacturability, and start to reduce
manufacturing costs.

   In order to accomplish this, we had to complete negotiations with some
vendors that were still not producing parts for LifePoint as late as the end
of September.  This was a little longer than expected and has put us slightly
behind in our start-up plan.  However, we have now successfully completed
negotiations with these vendors, and we are receiving the needed parts and
supplies. In October, we re-initiated manufacturing, and have now manufactured
several lots of the enhanced disposable Saliva Test Modules and improved
instruments. This allowed us to initiate the internal testing and validation
of the changes made in the product design. We are still in the process of
completing the internal part of the testing and validation of those changes,
but we have also just started some external validations as well.  Although we
have now re-initiated manufacturing of the enhanced instruments and
disposables, our plan is that we will not aggressively scale-up production
until we have not only fully tested and validated the system internally, but
also have validation from our field test sites.

   As we outlined in our August letter, only after these validations have been
completed, we will then get the enhanced product into the hands of current
customers and distributors.  Therefore, we would expect to be making shipments
of instruments during the quarter starting January 1, 2004 at the earliest. The
initial focus is to support the current instruments in the field that might
require a field upgrade or instrument replacement.

   The great news is that the testing to date indicates that the product design
changes have effected the product improvements we expected, especially as
relates to aspiration, although we still have more extensive field-testing to
complete the field validation. We believe that we are well on our way to
meeting our second major objective, to provide our customers and distributors
with an enhanced, proven test system as quickly as possible.

   We continue to validate our new automated Manufacturing Resource Planning
System. This software should reduce our working capital requirements, by
improving our ordering patterns of raw materials and parts so that we enhance
our ability to meet market demand without incurring excess inventory. It will
also give us more immediate and better visibility to the status of materials,
work-in-progress, and final product inventory on a daily basis.

Regulatory / Quality Assurance

   Although we had expected to be able to submit the additional data needed
to complete our FDA 510(k) submissions during October, the delays in both
hiring personnel and in resolving vendor issues have put us a little behind in
meeting that objective.  We do expect to complete our submissions shortly (May
mislead). It is now expected that FDA clearance would not occur any sooner than
early next year. Keep in mind that FDA clearance is not material to LifePoint's
initial sales efforts.

Sales & Marketing

   We have now met with some of our international distributors and customers
and the good news is that the European market demand for the LifePoint IMPACT
Test System is still very strong.  Although we updated and focused our business
and marketing plans, we are now developing our tactical plans in conjunction
with our distributors in order to quickly generate maximum sales and reach
profitability at the lowest cost and with the least amount of risk.

   Our revised focus remains first the international markets since the customer
demand continues to be very strong. Over the last 6 months, our current or
pending distributors have remained committed to LifePoint, as we expect to
finalize a significant number of distribution agreements shortly.  Our
distributor network covers twenty-five countries in Europe and the Pacific Rim.
Some international distributor and customer evaluations will need to be repeated
and others re-started for completion. The meetings with our core distributors in
Western Europe have gone well and they are anxious to re-start these numerous
customers and country evaluations, as soon as their own testing is complete.

   Once LifePoint has completed the re-launch of its product into the large
international markets, we will then focus on our other priority sales
opportunity, the industrial workplace, prior to spending a lot of time on the
US law enforcement market. LifePoint believes, based on our initial marketing
and sales pilot programs last fall and winter, that the US market receptivity
for the IMPACT Test System is greatest in the industrial market, and it has the
added benefit of a rapid sales cycle.


Financials for Quarter Ended September 30, 2003

   The initial $2 million investment in July enabled us to cautiously restart
operations, and the September completion of the financing permitted us to deal
with most of our suppliers and to begin to recall many of our employees. With a
late start in the second quarter our rate of expenditure was still well below
that of prior years. The net loss of  $382 thousand for the quarter included
gains of $278 thousand resulting from the favorable settlement of a lawsuit and
$724 thousand from settlements of old accounts payable, without which the loss
for the quarter would have been $1.4 million, or ($0.04) per share, as compared
to $3.9 million in the same quarter the previous year, or ($0.11) per share. For
the six months, the loss was $2.4 million as compared to $7.2 million the
previous year.

   There has been no sales revenue during the current year. With the ramp-up of
operations still in process it would be unrealistic to expect any material sales
revenue in this current quarter.

   Our cash balance at the end of the quarter was $6.1 million after having
favorably settled many of our old accounts payable and was close to our plan.

   With the completion of the recent financing, and the continued commitment of
the staff, investors, distributors and customers, the management team remains
confident that the Company's activities will culminate in long-term added value
for the stockholders. With the recent addition of, experienced personnel, the
re-launch of an enhanced product that the market is still patiently waiting for,
and a revised, focused business plan, LifePoint management looks forward to an
exciting second half of fiscal 2004. We remain very positive about the
prospects, progress and future of LifePoint

   We will continue to do our best to keep all of you apprised of what is
happening at LifePoint through press releases, stockholder updates, conference
presentations and our web site. Thank you again for your time.

Sincerely,

/s/Linda H. Masterson

Linda H. Masterson
Chief Executive Officer and President